Great Elm Group And 2 Other Stocks Under $2 Insiders Are Buying

The Dow Jones index closed higher by around 0.1% on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

Great Elm Group

• The Trade: Great Elm Group, Inc. GEG 10% owner Imperial Capital Group Holdings II, LLC acquired a total of 124,090 shares an average price of $1.96. To acquire these shares, it cost around $238,539.
• What’s Happening: On Feb. 13, Great Elm Group posted a loss for the second quarter.
• What Great Elm Group Does: Great Elm Group Inc operates as a holding company. It focuses on growing a scalable and diversified portfolio of long-duration, permanent capital vehicles across corporate credit, specialty finance, real estate, and other asset classes.

Earth Science Tech

• The Trade: Earth Science Tech, Inc. ETST CEO Giorgio R. Saumat acquired a total of 15,000 shares at at an average price of $0.08. To acquire these shares, it cost around $1,199.
• What’s Happening: On Jan. 29, Earth Science Tech announced a $5 million common stock repurchase program.
• What Earth Science Tech Does: Earth Science Tech Inc is a diversified holding company. Currently, the company is focused on emerging prospects in the health and wellness industry.

Check This Out: Dell, SoundHound AI And 3 Stocks To Watch Heading Into Friday

Emmaus Life Sciences

• The Trade: Emmaus Life Sciences, Inc. EMMA Co-President and COO Willis C Lee acquired a total of 115,200 shares at an average price of $0.13. The insider spent around $14,694 to buy those shares.
• What’s Happening: On Feb. 2, Emmaus Life Sciences received marketing authorization for Puerto Rico.
• What Emmaus Life Sciences Does: Emmaus Life Sciences Inc is a biopharmaceutical company engaged in the discovery, development, and commercialization of new treatments and therapies primarily for rare and orphan diseases.

Don’t forget to check out our premarket coverage here